Cargando…
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
With proteasome inhibitors (PIs) becoming clinically available since 2003, outcomes for patients with multiple myeloma (MM) have dramatically changed, improving quality of life and survival. Despite the impressive treatment success, however, almost all MM patients who initially respond to these PIs...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297691/ https://www.ncbi.nlm.nih.gov/pubmed/34308274 http://dx.doi.org/10.20517/cdr.2021.27 |